Lyra Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Lyra Therapeutics, Inc. (LYRA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are LYRA insiders buying or selling?
In the last 12 months, Lyra Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 4 sales ($535.0K) — net selling of $535.0K. Since May 2020, Trabud has recorded 23 Form 4 filings for LYRA: 17 buys ($84.7M) and 6 sells ($555.1K).
Source: SEC EDGAR Form 4
Key Statistics (May 2020 – Jan 8, 2026)
Total Form 4 filings
23
SEC EDGAR
Insider filers
10
Insider buys (17)
$84.7M
Insider sells (6)
$555.1K
Insider sentiment
Net buyingNet insider flow of $84.2M in net buying since May 2020, and $535.0K in net selling over the last 12 months.
Recent LYRA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Jason Cavalier | Chief Financial Officer | Sale | 769 | $3.36 | $2.6K | SEC ↗ |
| Jan 8, 2026 | Maria Palasis | President & CEO | Sale | 1.7K | $3.36 | $5.7K | SEC ↗ |
| Nov 13, 2025 | Joseph Edelman | 10% Owner | Sale | 45.9K | $3.98 | $182.5K | SEC ↗ |
| Nov 10, 2025 | Joseph Edelman | 10% Owner | Sale | 70.4K | $4.89 | $344.2K | SEC ↗ |
| Jul 15, 2025 | Maria Palasis | President & CEO | Sale | 1.6K | $8.91 | $13.9K | SEC ↗ |
| Jul 15, 2025 | Jason Cavalier | Chief Financial Officer | Sale | 684 | $8.91 | $6.1K | SEC ↗ |
| Nov 13, 2023 | Harlan Waksal | Executive Chair | Purchase | 25.0K | $2.96 | $74.1K | SEC ↗ |
| Jun 2, 2023 | Richard A Damore | 10% Owner | Purchase | 1.8M | $2.43 | $4.4M | SEC ↗ |
| Jun 2, 2023 | Edward T Anderson | Director, 10% Owner | Purchase | 1.8M | $2.43 | $4.4M | SEC ↗ |
| Jun 2, 2023 | Joseph Edelman | Director, 10% Owner | Purchase | 3.6M | $2.49 | $9.0M | SEC ↗ |
| Jun 13, 2022 | Ann C Merrifield | Director | Purchase | 4.0K | $5.05 | $20.2K | SEC ↗ |
| May 17, 2022 | Ann C Merrifield | Director | Purchase | 3.8K | $4.83 | $18.5K | SEC ↗ |
| Apr 14, 2022 | Joseph Edelman | Director, 10% Owner | Purchase | 5.9M | $4.22 | $25.0M | SEC ↗ |
| Apr 14, 2022 | Richard A Damore | 10% Owner | Purchase | 2.4M | $4.22 | $10.0M | SEC ↗ |
| Apr 14, 2022 | Edward T Anderson | Director, 10% Owner | Purchase | 2.5M | $4.22 | $10.5M | SEC ↗ |
| Apr 13, 2022 | Harlan Waksal | Executive Chair | Purchase | 237.0K | $4.22 | $1000.0K | SEC ↗ |
| Jun 22, 2021 | Ann C Merrifield | Director | Purchase | 3.5K | $8.97 | $31.4K | SEC ↗ |
| Dec 17, 2020 | Nancy Lynn Snyderman MD | Director | Purchase | 1.0K | $9.72 | $10.0K | SEC ↗ |
| May 29, 2020 | Joseph Edelman | Director, 10% Owner | Purchase | 625.0K | $16.00 | $10.0M | SEC ↗ |
| May 15, 2020 | Soleus Private Equity GP I, LLC | 10% Owner | Purchase | 138.1K | $16.00 | $2.2M | SEC ↗ |
| May 6, 2020 | NBVM GP, LLC | 10% Owner | Purchase | 225.8K | $16.00 | $3.6M | SEC ↗ |
| May 6, 2020 | Edward T Anderson | Director, 10% Owner | Purchase | 225.8K | $16.00 | $3.6M | SEC ↗ |
| May 6, 2020 | Polaris Venture Management Co. V, L.L.C. | 10% Owner | Purchase | 52.8K | $16.00 | $845.2K | SEC ↗ |
Showing the 23 most recent of 23 Form 4 filings for Lyra Therapeutics, Inc..
Most active LYRA insiders
- Joseph Edelman5 filings
- Ann C Merrifield3 filings
- Edward T Anderson3 filings
- Richard A Damore3 filings
- Harlan Waksal2 filings
Ask anything about LYRA insider activity
Use Trabud's AI agent to query Lyra Therapeutics, Inc.'s Form 4 history in plain English — "Show me LYRA CEO purchases this year" or compare it against any other ticker.
Open the AI agentLYRA insider trading FAQ
Are Lyra Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Lyra Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 4 sales ($535.0K) — net selling of $535.0K. Since May 2020, Trabud has recorded 23 Form 4 filings for LYRA: 17 buys ($84.7M) and 6 sells ($555.1K). Over the full record that is net buying of $84.2M.
How many insiders trade LYRA stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Lyra Therapeutics, Inc.. The most recent filing was accepted on Jan 8, 2026.
Where does Trabud get LYRA insider trading data?
All LYRA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.